Phase 2 Data Shows IMNN-001 Overcomes IL-12 Safety Barriers in Ovarian Cancer
IMNN is trading near its 52-week low of $1.7 (6.5% above the low) on light trading volume (0.3× avg).
Summary
Imunon reported positive preliminary Phase 2 MRD data for IMNN-001 in frontline ovarian cancer, showing a lower MRD-positive rate (44% vs 67%), higher ctDNA clearance (87.5% vs 62.5%), and 100% no evidence of disease rate versus 56% in control. The safety profile remains clean with no cytokine release syndrome or serious immune-related events, reinforcing the drug's differentiation. This builds on the May 12 Phase 2 OVATION 2 data and FDA alignment on Phase 3, adding translational evidence from a new Break Through Cancer study. With a market cap under $10M and a going concern warning, positive data is critical for financing and partnership prospects. The ongoing Phase 3 OVATION 3 trial is rapidly recruiting, and these results strengthen the case for IMNN-001's potential in a high-unmet-need indication.
At the time of this announcement, IMNN was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $1.70 to $8.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.